Inhibrx Biosciences Q4 net loss narrows as expenses fall

Inhibrx Biosciences

19/03/2026 20:09

Overview

Biopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declined

Company's R&D and G&A expenses fell due to lower clinical trial and legal costs

Company ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026

Result Drivers

LOWER CLINICAL TRIAL COSTS - Co said Q4 R&D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completion

REDUCED CONTRACT MANUFACTURING - Co attributed lower R&D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106

CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&A expenses dropped as legal proceedings ended, removing prior period costs

Company press release: ID:nPn7j3qZ1a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
Miss
-$2.11
-$2.08 (1 Analyst)
Q4 Net Income
Miss
-$32.83 mln
-$32.22 mln (1 Analyst)
Q4 Operating Income
Beat
-$30.92 mln
-$34.15 mln (1 Analyst)
Q4 Operating Expenses
$30.92 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)